93 related articles for article (PubMed ID: 30865134)
1. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Tsang VHM
Curr Opin Oncol; 2019 May; 31(3):236-242. PubMed ID: 30865134
[TBL] [Abstract][Full Text] [Related]
2. Management of treatment-related toxicities in advanced medullary thyroid cancer.
Brose MS; Bible KC; Chow LQM; Gilbert J; Grande C; Worden F; Haddad R
Cancer Treat Rev; 2018 May; 66():64-73. PubMed ID: 29704768
[TBL] [Abstract][Full Text] [Related]
3. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients.
Resteghini C; Cavalieri S; Galbiati D; Granata R; Alfieri S; Bergamini C; Bossi P; Licitra L; Locati LD
Best Pract Res Clin Endocrinol Metab; 2017 Jun; 31(3):349-361. PubMed ID: 28911730
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect.
Højer Wang L; Wehland M; Wise PM; Infanger M; Grimm D; Kreissl MC
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768635
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Miles DR; Lacy SA; Wada DR; Milwee S; Yaron Y; Nguyen LT
Cancer Chemother Pharmacol; 2017 Aug; 80(2):295-306. PubMed ID: 28634649
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria is a late-onset adverse event in patients treated with cabozantinib.
Cappagli V; Moriconi D; Bonadio AG; Giannese D; La Manna G; Egidi MF; Comai G; Vischini G; Bottici V; Elisei R; Viola D
J Endocrinol Invest; 2021 Jan; 44(1):95-103. PubMed ID: 32363491
[TBL] [Abstract][Full Text] [Related]
7. Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Grande E; Kreissl MC; Filetti S; Newbold K; Reinisch W; Robert C; Schlumberger M; Tolstrup LK; Zamorano JL; Capdevila J
Adv Ther; 2013 Nov; 30(11):945-66. PubMed ID: 24249433
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
de Castroneves LA; Negrão MV; de Freitas RM; Papadia C; Lima JV; Fukushima JT; Simão EF; Kulcsar MA; Tavares MR; Jorge AA; de Castro G; Hoff PM; Hoff AO
Thyroid; 2016 Mar; 26(3):414-9. PubMed ID: 26701095
[TBL] [Abstract][Full Text] [Related]
9. Gastropharyngeal Anastomotic Leak in Medullary Thyroid Carcinoma Following Initiation of a Tyrosine Kinase Inhibitor: A Case Report of an Unusual Side Effect of Cabozantinib.
Ackerman J; Kent S; Walker P
Ann Otol Rhinol Laryngol; 2020 Jul; 129(7):657-661. PubMed ID: 32037846
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
11. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
Krajewska J; Olczyk T; Jarzab B
Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165
[TBL] [Abstract][Full Text] [Related]
12. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
Dadu R; Hu MN; Grubbs EG; Gagel RF
Recent Results Cancer Res; 2015; 204():227-49. PubMed ID: 26494392
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis.
Miles D; Jumbe NL; Lacy S; Nguyen L
Clin Pharmacokinet; 2016 Jan; 55(1):93-105. PubMed ID: 26149244
[TBL] [Abstract][Full Text] [Related]
14. Management of Medullary Thyroid Cancer.
Viola D; Elisei R
Endocrinol Metab Clin North Am; 2019 Mar; 48(1):285-301. PubMed ID: 30717909
[TBL] [Abstract][Full Text] [Related]
15. Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer.
Lacouture ME; Ciccolini K; Kloos RT; Agulnik M
Thyroid; 2014 Sep; 24(9):1329-40. PubMed ID: 24902006
[TBL] [Abstract][Full Text] [Related]
16. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).
Shah RR; Morganroth J; Shah DR
Drug Saf; 2013 May; 36(5):295-316. PubMed ID: 23620167
[TBL] [Abstract][Full Text] [Related]
18. Medullary Thyroid Cancer: Overview and Case Study of a Rare Cancer.
Jakobs L
Clin J Oncol Nurs; 2018 Apr; 22(2):E37-E43. PubMed ID: 29547606
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
20. Thyroid carcinoma, version 2.2014.
Tuttle RM; Haddad RI; Ball DW; Byrd D; Dickson P; Duh QY; Ehya H; Haymart M; Hoh C; Hunt JP; Iagaru A; Kandeel F; Kopp P; Lamonica DM; Lydiatt WM; McCaffrey J; Moley JF; Parks L; Raeburn CD; Ridge JA; Ringel MD; Scheri RP; Shah JP; Sherman SI; Sturgeon C; Waguespack SG; Wang TN; Wirth LJ; Hoffmann KG; Hughes M
J Natl Compr Canc Netw; 2014 Dec; 12(12):1671-80; quiz 1680. PubMed ID: 25505208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]